中医药防治大肠癌术后复发转移前瞻性队列研究  

Prospective Cohort Study on TCM to Protecting Relapse and Metastasis of Postoperative Colorectal Cancer

作　　者：梁碧颜[1] 吴煜[2] 雒琳[2] 杨宇飞[1] 张侠[3] 刘端祺[3] 

机构地区：[1]中国中医科学院,北京100700 [2]中国中医科学院西苑医院,北京100091 [3]中国人民解放军北京军区总医院,北京100700

出　　处：《中国中医药信息杂志》2008年第11期12-14,共3页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：首都医学发展科研基金;北京医学卫生科技自主创新和普及推广项目(03-Ⅲ-20)

摘　　要：目的研究中医药在大肠癌根治术后巩固治疗中的临床价值。方法采用前瞻性队列研究设计,选取中国中医科学院西苑医院门诊和病房的84例大肠癌术后病例(治疗组)与北京军区总医院的78例病例(对照组)进行同期对照,就复发转移率和无病生存率进行观察。选择9个可能对大肠癌术后无病生存产生影响的因素,通过COX模型进行多因素分析。结果治疗组1、2、3年复发转移率分别为0、4.08%、20.00%,对照组分别为5.12%、22.91%、36.11%,即治疗组1、2、3年无病生存率分别是100%、95.91%、80.00%,对照组为94.87%、77.08%、63.88%。影响患者术后无病生存的主要因素为淋巴结是否转移和治疗方式。结论中医药联合放化疗对于预防大肠癌的复发转移具有积极和重要的意义。Objective To study the clinical importance of TCM used in solidified therapy of colorectal cancer after radical resection. Method Prospective cohort study was applied to the trial, 84 cases in Xiyuan Hospital were selected to compare with 78 cases in western medicine hospital in the same time. The rates of relapse-metastasis and disease free survival of two groups were observed. Nine possible factors influencing disease-free survival were selected to analyze with COX regression model. Results 1-year, 2-year and 3-year relapse-metastasis rate of the teatment group were 0, 4.08% and 20% respectively, those were 5.12%, 22.91% and 36.11% in the control group. 1-year, 2-year and 3-year disease-free survival rate of teatment group were 100%, 95.91% and 80%, those were 94.87%, 77.08% and 63.88% in the control group. The main prognostic factors were lymph nodes metastasis and therapy. Conclusion TCM used in postoperative colorectal cancer could prevent relapse and metastasis.

关 键 词：大肠癌 复发转移 前瞻性队列研究 COX模型 

分 类 号：R273.53[医药卫生—中西医结合]